Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Psoriasis is a common inflammatory skin disease with multiple comorbidities, including
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …

Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …

Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema.
It impairs patients' quality of life enormously. It has been recognized not only as a skin …

Background Significantly more patients with moderate‐to‐severe plaque psoriasis treated
with the interleukin (IL)‐17A inhibitor ixekizumab vs. the IL‐23p19 inhibitor guselkumab in …

Eleven biologic drugs are currently approved for psoriasis management. Real‐life studies
are needed to guide clinicians in choosing a tailored‐tail therapy. The aim of our …

Psoriasis is a T cell–mediated disease with autoimmune characteristics modulated by
genetic susceptibility along with environmental triggers. Inflammatory pathways marked with …

Psoriasis is a chronic inflammatory skin condition associated with immune dysregulation.
The immunologic cascade mediated by the interleukin (IL)-17 pathway plays a critically …

Psoriasis is a multifactorial recalcitrant inflammatory skin disease characterized by
bothersome scaly reddish plaques especially on frequently chafed body parts, such as the …

Background Real-life studies in psoriasis are lacking. Many monoclonal antibodies targeting
tumor-necrosis factor (TNF)-alpha, interleukin 17, and 23 are approved drugs for psoriasis …